放疗联合抗PD-L1抗体在非小细胞肺癌中协同增强抗肿瘤效应
研究探讨PD-L1在NSCLC放疗抵抗中的作用及放疗联合抗PD-L1抗体的抗肿瘤效应。体外和体内实验显示常规分割放疗后PD-L1表达升高,联合抗PD-L1抗体可协同增强抗肿瘤免疫。回顾性队列中PD-L1阴性患者放疗后客观缓解率和疾病控制率均显著高于PD-L1阳性患者。
要点
- 常规分割放疗后PD-L1在体内外表达均升高。
- 小鼠模型中放疗联合抗PD-L1抗体协同增强抗肿瘤免疫。
- PD-L1阴性患者放疗后客观缓解率88% vs PD-L1阳性43.1%(p<0.001)。
核心结论
- 常规分割放疗联合抗PD-L1抗体在NSCLC中显示出协同抗肿瘤免疫效应。
- PD-L1表达可能是NSCLC放疗治疗反应的重要临床预测因素。
研究设计与样本
- 研究通过小干扰RNA转染、免疫组化、Western blot和免疫共沉淀探讨放疗后PD-L1表达的调控机制。
- 在小鼠模型中评估放疗与抗PD-L1抗体的协同效应。
- 在回顾性队列中检测接受同步放化疗患者的肿瘤标本PD-L1表达。
主要发现
- 常规分割放疗后PD-L1在体内和体外表达均升高。
- 小鼠模型中放疗联合抗PD-L1抗体通过促进CD8阳性T细胞浸润、减少髓源性抑制细胞和肿瘤浸润调节性T细胞积聚协同增强抗肿瘤免疫。
- 放疗可能通过磷脂酰肌醇3-激酶/AKT和信号转导与转录激活因子3通路上调PD-L1表达。
- PD-L1可刺激细胞迁移并促进上皮-间质转化过程诱导放疗抵抗。
- 下调PD-L1可通过促进凋亡减轻放疗抵抗。
关键数值与推荐
- PD-L1阴性患者放疗后客观缓解率88% vs PD-L1阳性患者43.1%(p<0.001)。
- PD-L1阴性患者放疗后疾病控制率100% vs PD-L1阳性患者86.2%(p=0.026)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune escape frequently occurs and restricts the durability of the antitumor immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important immune checkpoint molecules that could cause tumor cells to escape the host immune response. The aim of the study was to explore the role of PD-L1 in radioresistance and the antitumor effect of combined radiotherapy and anti-PD-L1 therapy in NSCLC. METHODS: The role of the phosphoinositide 3-kinase/protein kinase B signal transducer and activator of transcription 3, epithelial-mesenchymal transition, and tripartite motif containing 21 in regulating PD-L1 expression after radiotherapy was investigated by small interfering-PD-L1-RNA transfection, immunohistochemistry, Western blot, and immunoprecipitation. The synergistic effect of radiotherapy and anti-PD-L1 antibody was evaluated in a mouse model. PD-L1 expression on tumor specimens was examined in a retrospective cohort of patients who received concurrent chemoradiotherapy. RESULTS: PD-L1 expression was increased in vivo and in vitro after conventionally fractionated radiation. Radiotherapy in combination with anti-PD-L1 antibody synergistically enhanced antitumor immunity by promoting CD8-positive T-cell infiltration and reducing the accumulation of myeloid-derived suppressor cells and tumor-infiltrating regulatory T cells in a mouse model. Radiotherapy may up-regulate PD-L1 expression through the phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3 pathways. PD-L1 may also stimulate cell migration and facilitate the epithelial-mesenchymal transition process to induce radioresistance. Moreover, down-regulating PD-L1 could alleviate radioresistance by promoting apoptosis. Intriguingly, patients with negative PD-L1 expression had a significantly higher objective response rate (88% versus 43.1% [p < 0.001]) and disease control rate (100% versus 86.2% [p = 0.026]) than those with positive PD-L1 expression after delivery of radiotherapy. CONCLUSIONS: Conventionally fractionated radiotherapy in combination with anti-PD-L1 antibody shows a synergistic antitumor immunity in NSCLC. Furthermore, PD-L1 expression may be a significant clinical predictive factor for treatment response to radiotherapy in NSCLC.
引用
- Gong X, Li X, Jiang T, et al. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28478231. doi:10.1016/j.jtho.2017.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。